Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations (Q39135505)

9 September 2017

title

Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations (English)

1 reference

9 September 2017

0 references

1

Andy Crump

1 reference

9 September 2017

publication date

15 February 2017

1 reference

The Journal of Antibiotics

9 September 2017

published in

1 reference

9 September 2017

volume

70

1 reference

9 September 2017

issue

5

1 reference

9 September 2017

page(s)

495-505

1 reference

Ivermectin: A Potent New Antiparasitic Agent

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

21 January 2018

Ivermectin: an update

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ivermectin as an antiparasitic agent for use in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

The life and times of ivermectin - a success story

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ivermectin 20 years on: maturation of a wonder drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ivermectin: 25 years and still going strong

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ivermectin, 'wonder drug' from Japan: the human use perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

The onchocerciasis chronicle: from the beginning to the end?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ivermectin: panacea for resource-poor communities?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

A Splendid Gift from the Earth: The Origins and Impact of the Avermectins (Nobel Lecture).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Avermectins, New Family of Potent Anthelmintic Agents: Producing Organism and Fermentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Avermectins, New Family of Potent Anthelmintic Agents: Isolation and Chromatographic Properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Avermectins, New Family of Potent Anthelmintic Agents: Efficacy of the B 1a Component

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

The geographic distribution of onchocerciasis in the 20 participating countries of the African Programme for Onchocerciasis Control: (2) pre-control endemicity levels and estimated number infected

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

African programme for onchocerciasis control 1995-2015: updated health impact estimates based on new disability weights

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Control, elimination, and eradication of river blindness: scenarios, timelines, and ivermectin treatment needs in Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

African Program for Onchocerciasis Control 1995-2010: Impact of Annual Ivermectin Mass Treatment on Off-Target Infectious Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Resistance of field strains of Haemonchus contortus to ivermectin, closantel, rafoxanide and the benzimidazoles in South Africa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Avermectin use in aquaculture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Lymphatic filariasis and onchocerciasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

The pharmacokinetics and interactions of ivermectin in humans--a mini-review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Pharmacological characterization of the Haemonchus contortus GABA-gated chloride channel, Hco-UNC-49: modulation by macrocyclic lactone anthelmintics and a receptor for piperazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Identification of two novel Drosophila melanogaster histamine-gated chloride channel subunits expressed in the eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

A novel chloride channel in Drosophila melanogaster is inhibited by protons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

High level expression of a glutamate-gated chloride channel gene in reproductive tissues of Brugia malayi may explain the sterilizing effect of ivermectin on filarial worms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

The Effects of Ivermectin on Brugia malayi Females In Vitro: A Transcriptomic Approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ivermectin disrupts the function of the excretory-secretory apparatus in microfilariae of Brugia malayi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

How do the macrocyclic lactones kill filarial nematode larvae?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Killing filarial nematode parasites: role of treatment options and host immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Helminth immunoregulation: the role of parasite secreted proteins in modulating host immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Susceptibility and immunity to helminth parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Differential cytokine and antibody responses to adult and larval stages of Onchocerca volvulus consistent with the development of concomitant immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Immunocompetence may be important in the effectiveness of Mectizan (ivermectin) in the treatment of human onchocerciasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Pathogenesis and host responses in human onchocerciasis: impact of Onchocerca filariae and Wolbachia endobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Oral myiasis treated with ivermectin: case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Therapeutic potential of myrrh and ivermectin against experimental Trichinella spiralis infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ivermectin as a systemic insecticide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ivermectin mass drug administration to humans disrupts malaria parasite transmission in Senegalese villages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Plasmodium falciparum signal recognition particle components and anti-parasitic effect of ivermectin in blocking nucleo-cytoplasmic shuttling of SRP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Endectocides for malaria control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Establishment of the Ivermectin Research for Malaria Elimination Network: updating the research agenda

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ivermectin as a rodent feed-through insecticide for control of immature sand flies (Diptera: Psychodidae).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Effects of ivermectin on blood-feeding Phlebotomus papatasi, and the promastigote stage of Leishmania major.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Decrease in survival and fecundity of Glossina palpalis gambiensis vanderplank 1949 (Diptera: Glossinidae) fed on cattle treated with single doses of ivermectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ticks, ivermectin, and experimental Chagas disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Evidence for the presence of glutamatergic receptors in adult Schistosoma mansoni

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ivermectin binding sites in human and invertebrate Cys-loop receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Characterization of a truncated metabotropic glutamate receptor in a primitive metazoan, the parasitic flatworm Schistosoma mansoni

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Molluscicidal effect of ivermectin on Biomphalaria glabrata.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ivermectin causes Cimex lectularius (bedbug) morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

[Pathogenesis, clinical picture, and current therapy of rosacea].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Anti-inflammatory effects of ivermectin in mouse model of allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Nodding syndrome or disease? On the conceptualization of an illness-in-the-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Clinical, neurological, and electrophysiological features of nodding syndrome in Kitgum, Uganda: an observational case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Head nodding syndrome and river blindness: a parasitologic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Tropical Diseases. Mystery disease haunts region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

An Epidemiologic Investigation of Potential Risk Factors for Nodding Syndrome in Kitgum District, Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Nodding syndrome since 2012: recent progress, challenges and recommendations for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ivermectin inhibits AMPA receptor-mediated excitotoxicity in cultured motor neurons and extends the life span of a transgenic mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

New insights into the structural bases of activation of Cys-loop receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Functional characterization of ivermectin binding sites in α1β2γ2L GABA(A) receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

The importin α/β-specific inhibitor Ivermectin affects HIF-dependent hypoxia response pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ivermectin inhibits growth of Chlamydia trachomatis in epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ivermectin lacks antituberculous activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Measurements of the in vitro anti-mycobacterial activity of ivermectin are method-dependent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

In-vitro activity of avermectins against Mycobacterium ulcerans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Antitumor effect of avermectins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional Signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1/Akt Axis in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ivermectin exhibits potent anti-mitotic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Emerging Frontiers in Drug Delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ivermectin in human medicine, an overview of the current status of its clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ivermectin-loaded lipid nanocapsules: toward the development of a new antiparasitic delivery system for veterinary applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Long-term delivery of ivermectin by use of poly(D,L-lactic-co-glycolic)acid microparticles in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Delivery of ivermectin by injectable microspheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Microspheres of corn protein, zein, for an ivermectin drug delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Screening for an ivermectin slow-release formulation suitable for malaria vector control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Experimental study of pharmacokinetics of external, whole-body bathing application of ivermectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Oral delivery of ivermectin using a fast dissolving oral film: Implications for repurposing ivermectin as a pharmacotherapy for alcohol use disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

7 January 2021

Chemotherapy in the treatment, control, and elimination of human onchocerciasis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

7 January 2021

A Case of Orbital Myiasis in Recurrent Eyelid Basal Cell Carcinoma Invasive into the Orbit.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

7 January 2021

Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

7 January 2021

Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2017.11

7 January 2021

Identifiers

DOI

10.1038/JA.2017.11

1 reference

9 September 2017

1 reference